Q1 Earnings Estimate for ATNM Issued By HC Wainwright

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) – Analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Actinium Pharmaceuticals in a research report issued to clients and investors on Tuesday, March 31st. HC Wainwright analyst J. Pantginis anticipates that the company will post earnings of ($0.22) per share for the quarter. The consensus estimate for Actinium Pharmaceuticals’ current full-year earnings is ($1.41) per share. HC Wainwright also issued estimates for Actinium Pharmaceuticals’ Q2 2026 earnings at ($0.25) EPS, Q3 2026 earnings at ($0.29) EPS and Q4 2026 earnings at ($0.33) EPS.

Separately, Stephens reaffirmed an “overweight” rating and issued a $5.00 price target on shares of Actinium Pharmaceuticals in a research report on Tuesday. Two analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Actinium Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $4.50.

Actinium Pharmaceuticals Trading Up 0.5%

NYSE ATNM opened at $1.00 on Wednesday. Actinium Pharmaceuticals has a 12 month low of $0.95 and a 12 month high of $1.95. The stock has a market cap of $31.05 million, a P/E ratio of -0.72 and a beta of -0.31. The stock’s fifty day moving average price is $1.14 and its 200-day moving average price is $1.35.

Hedge Funds Weigh In On Actinium Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the company. Squarepoint Ops LLC bought a new position in Actinium Pharmaceuticals in the 4th quarter valued at approximately $89,000. Renaissance Technologies LLC increased its holdings in shares of Actinium Pharmaceuticals by 35.4% in the 4th quarter. Renaissance Technologies LLC now owns 390,784 shares of the company’s stock worth $531,000 after purchasing an additional 102,154 shares in the last quarter. Goldman Sachs Group Inc. bought a new stake in shares of Actinium Pharmaceuticals in the 4th quarter worth $96,000. AM Investment Strategies LLC purchased a new position in shares of Actinium Pharmaceuticals in the fourth quarter worth $40,000. Finally, Bailard Inc. purchased a new position in shares of Actinium Pharmaceuticals in the fourth quarter worth $79,000. 27.50% of the stock is currently owned by hedge funds and other institutional investors.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on the development of targeted radiopharmaceutical therapies for patients with hematologic malignancies. The company’s proprietary technology platform combines monoclonal antibodies with radioisotopes to deliver highly potent, cell?killing radiation directly to cancer cells while sparing healthy tissues. Actinium’s lead product candidate, Iomab?B, is being evaluated as a conditioning regimen for older patients with acute myeloid leukemia (AML) who are ineligible for standard bone marrow transplants.

In addition to Iomab?B, Actinium’s pipeline includes Actimab?A, an anti?CD33 antibody labeled with the radioisotope bismuth?213 for the treatment of relapsed or refractory AML.